Melanoma Surgery in India
Get Melanoma Surgery at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Melanoma Surgery in UAE
Melanoma Surgery at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Melanoma surgery encompasses a spectrum of oncological procedures—from wide local excision and sentinel lymph node biopsy to radical lymphadenectomy and isolated limb perfusion—designed to achieve clear surgical margins and prevent systemic metastasis in patients diagnosed with cutaneous or mucosal melanoma. Across major cancer centers in India and the UAE, 5-year survival rates for Stage I and Stage II melanoma following definitive surgical resection exceed 90% and 65% respectively, with advanced adjuvant immunotherapy protocols further improving outcomes for higher-stage disease. GAF Healthcare connects international patients to JCI- and NABH-accredited institutions in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi, offering end-to-end oncology coordination, second-opinion facilitation, and cost-transparent treatment pathways for melanoma at a fraction of Western prices.
Hospital Stay: 3–10 days (varies by stage: 3–5 days for wide local excision with SLNB; up to 10 days for radical lymphadenectomy or reconstructive flap surgery) • Total Stay in Country (Fit-to-Fly): 2–6 weeks (Stage I–II simple excision: 2–3 weeks; Stage III with lymph node dissection or reconstruction: 4–6 weeks; adjuvant therapy patients reviewed individually) • Success Rate: 90%+ (Stage I); 65–80% (Stage II); 40–60% (Stage III with adjuvant immunotherapy)
What Is It?
Melanoma is a malignancy arising from melanocytes—the pigment-producing cells found predominantly in the skin but also in the ocular uvea, mucous membranes, and meninges. Cutaneous melanoma accounts for approximately 1–2% of all skin cancers by incidence but is responsible for the overwhelming majority of skin cancer deaths, owing to its propensity for early lymphatic and hematogenous dissemination. The four principal histological subtypes—superficial spreading, nodular, lentigo maligna, and acral lentiginous melanoma—differ in growth pattern and anatomical predilection, but all share the capacity for vertical-phase invasion once Breslow thickness exceeds 1 mm or Clark level IV is reached. Key molecular drivers include mutations in BRAF (V600E in approximately 50% of cutaneous cases), NRAS, c-KIT, and NF1, which have reshaped both surgical planning and adjuvant systemic therapy selection.
The physiological consequences of unresected melanoma extend well beyond the primary lesion. Regional lymph node involvement (Stage III) triggers immune cascade dysregulation, while distant metastases (Stage IV) most commonly colonize the lungs, liver, brain, and bone, causing organ-specific morbidity. The tumor microenvironment is characterized by high immunogenicity, which is why melanoma was the index cancer for modern immune checkpoint inhibitor therapy. Staging follows the AJCC 8th Edition TNM system, incorporating Breslow thickness, ulceration status, mitotic rate, satellite/in-transit lesions, and the number and burden of involved lymph nodes. Accurate staging drives surgical decision-making and determines eligibility for adjuvant pembrolizumab, nivolumab, or targeted BRAF/MEK inhibitor combinations (dabrafenib plus trametinib).
The standard of care for resectable melanoma is surgical excision with histologically confirmed clear margins, the width of which is evidence-based: 0.5 cm for melanoma in situ, 1 cm for Breslow ≤1 mm, 1–2 cm for 1.01–2 mm thickness, and 2 cm for tumors >2 mm. Sentinel lymph node biopsy (SLNB) is recommended for tumors ≥0.8 mm or those with adverse features (ulceration, mitoses) to stage regional nodal basins without the morbidity of elective complete lymph node dissection. Completion lymph node dissection (CLND) is now selectively reserved based on the MSLT-II trial data and individual nodal tumor burden. Adjuvant systemic therapy post-surgery and radiation therapy for selected nodal or mucosal sites complete the multidisciplinary treatment framework practiced at top-tier centers in India and the UAE.
Candidates
• ELIGIBLE PATIENTS:
• Histologically confirmed melanoma at any AJCC stage (I–IV) where surgical resection is feasible with curative or cytoreductive intent
• Patients with primary tumor Breslow thickness ≥0.8 mm or any thickness with ulceration or high mitotic rate requiring SLNB mapping
• Stage III patients with clinically or biopsy-proven regional lymph node metastasis requiring therapeutic lymph node dissection (inguinal, axillary, or cervical)
• Patients with oligometastatic Stage IV disease (isolated lung, adrenal, or subcutaneous metastases) suitable for metastasectomy combined with systemic immunotherapy
• Patients with desmoplastic melanoma or acral lentiginous melanoma requiring wide margins and reconstructive flap or skin graft coverage
• Patients seeking second opinions on margin adequacy or re-excision after prior incomplete resection
• International patients who have completed initial biopsy and pathology abroad and require definitive surgical staging and treatment
• REQUIRED PRE-OPERATIVE DIAGNOSTICS:
• Dermatopathology review of primary biopsy with Breslow thickness, Clark level, ulceration status, mitotic rate, and perineural/lymphovascular invasion reporting
• BRAF V600E/K mutation testing (ideally full BRAF/NRAS/NF1/c-KIT panel via next-generation sequencing) for all Stage IIB and above
• Whole-body PET-CT scan (18F-FDG) for Stage IIB–IV staging and detection of occult nodal or distant metastases
• MRI brain with gadolinium contrast for Stage III–IV to exclude cerebral metastases
• Lymphoscintigraphy with dynamic planar imaging and SPECT-CT for sentinel lymph node mapping of the draining nodal basin prior to SLNB
• Complete blood count, comprehensive metabolic panel, LDH (elevated LDH is an independent poor prognostic marker in Stage IV)
• CT chest/abdomen/pelvis with contrast as an alternative staging workup where PET-CT is not available
• Baseline ECHO and pulmonary function tests for patients planned for adjuvant immunotherapy or isolated limb perfusion
• CONTRAINDICATIONS & CAUTIONS:
• Unresectable Stage IV disease with high systemic burden where first-line systemic immunotherapy (anti-PD-1 ± anti-CTLA-4) should precede surgical consideration
• Severe cardiac or pulmonary comorbidities precluding general anesthesia (individualized risk assessment by anesthesiology team required)
• Active autoimmune conditions (relative contraindication to concurrent immunotherapy, not to surgery itself)
• Coagulopathies or anticoagulation regimens requiring perioperative bridging management
• Pregnancy (requires multidisciplinary maternal-fetal medicine consultation; surgery may proceed in selected cases)
Procedure
STANDARD SURGICAL APPROACHES:
• Wide Local Excision (WLE): The cornerstone of melanoma surgery. The primary lesion is excised en bloc with a margin of normal tissue calibrated to Breslow thickness per NCCN/ESMO guidelines (0.5–2 cm). Performed under local or regional anesthesia for thin lesions; general anesthesia for deeper tumors or complex anatomical sites (face, hands, feet, mucosa). Wound closure may be primary, or may require split-thickness skin grafting (STSG) or local rotational flaps where primary closure would compromise function or result in unacceptable deformity.
• Sentinel Lymph Node Biopsy (SLNB): The standard staging procedure for intermediate and thick melanomas. Dual-agent lymphatic mapping uses a combination of technetium-99m-labeled nanocolloid (injected the day prior with lymphoscintigraphy/SPECT-CT mapping) and intraoperative Patent Blue V or isosulfan blue dye injection at the primary site. The gamma probe identifies the hot sentinel node(s) for targeted excision with minimal morbidity. Alternatively, fluorescence-guided SLNB using indocyanine green (ICG) with near-infrared imaging is offered at advanced centers in India and the UAE, improving real-time intraoperative nodal visualization.
• Therapeutic Lymph Node Dissection (TLND): Indicated for clinically or radiologically involved regional lymph nodes. Axillary dissection (Levels I–III), inguinofemoral dissection (superficial ± deep iliac/obturator nodal clearance based on Cloquet's node status), and radical neck dissection (modified or selective) are performed. Based on MSLT-II and DeCOG-SLT trial data, immediate CLND following a positive SLNB is no longer routine; it is reserved for patients with high nodal tumor burden or extracapsular extension.
• Isolated Limb Perfusion (ILP) and Isolated Limb Infusion (ILI): For unresectable in-transit or satellite metastases confined to a limb. ILP uses a pump oxygenator to deliver high-dose melphalan (±TNF-alpha) via hyperthermic perfusion of the isolated limb vasculature, achieving locoregional drug concentrations 15–25 times higher than systemic delivery. ILI is a simpler catheter-based variant available at specialized centers. Complete response rates of 25–35% and overall response rates of 60–80% are reported.
• Reconstructive Surgery: Complex resections involving the face, scalp, digits, or plantar surface require concurrent oncoplastic reconstruction. Techniques include: pedicled or free myocutaneous flaps (anterolateral thigh flap, radial forearm free flap), tissue expansion, and digit reconstruction. India's major oncology centers house dedicated plastic and reconstructive surgery teams with high-volume melanoma reconstruction experience.
ADVANCED & MINIMALLY INVASIVE MODALITIES:
• Robotic-Assisted Lymphadenectomy: Available at select centers in India (Medanta, Fortis, Apollo) and the UAE (Cleveland Clinic Abu Dhabi, American Hospital Dubai). Robotic platforms (da Vinci Xi) enable inguinal and pelvic lymphadenectomy via smaller incisions, improving visualization in deep anatomical compartments and reducing postoperative lymphedema compared to open approaches, though open surgery remains the standard for complex dissections.
• Mohs Micrographic Surgery (MMS): Used selectively for lentigo maligna melanoma (melanoma in situ) of the face and acral sites where tissue conservation is critical. Staged excision with intraoperative margin assessment via rush permanent sections (slow Mohs technique) is preferred over true Mohs for invasive melanoma to allow complete vertical and radial margin evaluation.
• Stereotactic Radiosurgery (SRS) / CyberKnife for Brain Metastases: For oligo-metastatic Stage IV patients with 1–4 brain metastases, SRS (Gamma Knife, CyberKnife) delivers ablative radiation doses with sub-millimeter precision, avoiding the neurocognitive toxicity of whole-brain radiation therapy (WBRT). Available at Tata Memorial, HCG, and AIIMS in India, and at Burjeel Medical City and American Hospital Dubai in the UAE.
• Electrochemotherapy (ECT): An emerging modality combining bleomycin injection with reversible electroporation to enhance drug uptake in cutaneous and subcutaneous melanoma metastases, available at select oncology centers as a palliative or bridging treatment.
ADJUVANT SYSTEMIC THERAPIES (Surgical Context):
• BRAF V600-mutant patients (Stage IIB–III): Adjuvant dabrafenib + trametinib for 12 months post-resection reduces relapse risk by ~50%.
• BRAF wild-type and all resected Stage III–IV: Adjuvant pembrolizumab (anti-PD-1, 200 mg Q3W × 12 months) or nivolumab (240 mg Q2W × 12 months) per KEYNOTE-716 and CheckMate 238 data.
• Adjuvant ipilimumab (anti-CTLA-4) is available but has a less favorable toxicity profile and is increasingly superseded by anti-PD-1 monotherapy.
Cost of Melanoma Surgery: India vs. UAE
The cost of melanoma surgery varies significantly depending on the surgical stage, complexity of reconstruction, need for lymph node dissection or isolated limb perfusion, and whether adjuvant immunotherapy is initiated in-country. Both India and the UAE offer internationally accredited oncology programs with equivalent surgical expertise; the principal difference is pricing—India's public and private cancer centers deliver care at 50–65% lower cost than comparable UAE facilities, while the UAE offers a premium infrastructure, proximity for Middle Eastern and European patients, and luxury medical hospitality. The figures below reflect all-inclusive surgical packages (surgeon fees, anesthesia, operating room, pathology, hospital stay, and standard post-operative medications) and do not include adjuvant immunotherapy cycles, which are priced separately per protocol.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $3,500 – $12,000 | ~53% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $8,000 – $25,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL & CONSULTATION (Weeks 1–3 before travel):
• GAF Healthcare receives patient's biopsy pathology report, imaging (PET-CT, MRI brain), and mutation profiling results for virtual multidisciplinary tumor board review.
• Case is presented to a senior surgical oncologist (melanoma specialist) and a medical oncologist at the selected partner hospital.
• A written second opinion and treatment plan (surgical approach, reconstruction requirements, adjuvant therapy recommendation) is issued within 5–7 business days.
• GAF Healthcare assists with e-Medical Visa application (India) or UAE entry visa coordination. Hospital invitation letters and visa documentation provided within 48 hours of plan confirmation.
• Pre-travel instructions issued: medications to withhold (anticoagulants, aspirin 7–10 days pre-op), dietary guidance, compression stockings for DVT prophylaxis during long-haul flight.
PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3 in-country):
• Airport transfer by GAF Healthcare's dedicated medical concierge team.
• Day 1: Oncology outpatient consultation, clinical examination of primary lesion and regional lymph node basins, review of all external investigations.
• Day 2: Any required in-house investigations (repeat PET-CT if >8 weeks old, ECHO, pulmonary function tests, full blood workup, anesthesiology pre-assessment). Lymphoscintigraphy performed for SLNB mapping if SLNB is planned.
• Day 3: Surgical consent process (interpreter-assisted), marking of excision margins, pre-operative skin preparation. Admission to surgical ward. Anesthesia review and optimization.
PHASE 3 — SURGERY (Day 4 or 5):
• Wide Local Excision: Typically 1–3 hours under general or regional anesthesia. Intraoperative frozen section margin assessment where anatomically feasible. Wound closure or graft/flap reconstruction performed in the same operative session.
• SLNB Addition: Adds 30–60 minutes. Gamma probe and blue dye guidance; sentinel nodes sent for permanent section histopathology (results in 3–5 days) and immunohistochemistry (S-100, HMB-45, Melan-A).
• Lymph Node Dissection (if planned as primary procedure): 2–5 hours depending on basin and extent.
• Isolated Limb Perfusion: 4–6 hours including cannulation, perfusion circuit establishment, and decannulation.
PHASE 4 — IMMEDIATE POST-OPERATIVE RECOVERY (Days 5–10 in hospital):
• Day 1 post-op: Monitoring in surgical HDU or ICU (ILP patients); pain management with multimodal analgesia; DVT prophylaxis with low-molecular-weight heparin resumed 24–48 hours post-operatively.
• Day 2–3: Ambulation initiated; wound drains output monitored; soft diet resumed; lymphedema prophylaxis education for patients undergoing nodal dissection.
• Day 4–5: Drain removal when output <30 mL/24 hours; graft inspection and dressing change; dermatology and wound care team review.
• Day 5–7 (simple WLE ± SLNB): Discharge from hospital to hotel/accommodation. SLNB histopathology results reviewed with surgical oncologist; adjuvant therapy plan confirmed if node-positive.
• Day 8–10 (lymph node dissection or flap reconstruction): Discharge when wound is stable and patient demonstrates adequate self-care of wound site.
PHASE 5 — POST-DISCHARGE RECOVERY IN DESTINATION (Until Fit to Fly):
• Week 2: Outpatient wound review, suture removal (or confirmation of absorbable suture integrity); compression garment fitting for limb lymphedema prevention; first post-operative oncology consultation.
• Week 3: Final surgical oncologist clearance for international travel. For patients commencing adjuvant immunotherapy (pembrolizumab/nivolumab), Cycle 1 may be administered before departure if patient and oncologist agree; subsequent cycles can be administered in home country with GAF Healthcare-facilitated records transfer.
• Fit-to-Fly Milestones: Wound healed without dehiscence; no active infection; drain-free; DVT risk acceptable (compression stockings + LMWH or DOAC for long-haul flight); no active immunotherapy-related adverse events requiring on-site management.
PHASE 6 — LONG-TERM FOLLOW-UP PROTOCOL:
• Surveillance: Dermatology examination every 3 months for 2 years, then every 6 months for 3 years, then annually.
• Imaging: CT chest/abdomen/pelvis or PET-CT every 6 months for 3 years (Stage III–IV).
• GAF Healthcare provides telemedicine follow-up coordination between the treating surgeon in India/UAE and the patient's home oncologist; translated records and imaging CDs dispatched with patient on discharge.
Risks & Considerations
Melanoma surgery is generally well-tolerated, but patients and their families must be counseled on procedure-specific and stage-specific risks with full transparency. For wide local excision, the principal concerns are wound dehiscence (particularly over joints or following skin grafting), hematoma formation (1–3%), wound infection (2–5%), and graft failure requiring revision in 5–10% of reconstructed sites. Sentinel lymph node biopsy carries a false-negative rate of approximately 5–10%, meaning a negative SLNB does not guarantee absence of nodal micrometastasis; it also carries a small risk of lymphedema (<5%), seroma, and neurosensory changes at the biopsy site. Completion or therapeutic lymph node dissection carries significantly higher lymphedema risk—up to 30–40% for inguinofemoral dissections—along with wound breakdown in the groin (a notoriously challenging healing environment), deep vein thrombosis, and injury to adjacent neurovascular structures (femoral nerve, saphenous vein). Isolated limb perfusion (ILP) is associated with regional toxicity (limb erythema, blistering, compartment syndrome in 1–3%), systemic leak of melphalan causing transient bone marrow suppression, and, rarely, limb loss (<1%). Reconstructive flap surgery introduces risks of partial or total flap failure, donor site morbidity, and prolonged recovery. From an oncological perspective, the primary risk is inadequate surgical margin, which mandates re-excision and is associated with higher local recurrence rates. Patients with Stage III disease undergoing surgery face a 5-year relapse risk of 40–70% without adjuvant therapy, underscoring the importance of prompt initiation of pembrolizumab, nivolumab, or BRAF/MEK inhibitor therapy post-resection. Adjuvant immunotherapy itself introduces immune-related adverse events (irAEs)—colitis, pneumonitis, hepatitis, endocrinopathies—in 15–30% of patients, requiring proactive monitoring and, when severe, systemic corticosteroids. GAF Healthcare ensures all patients are comprehensively informed of these risks through pre-operative counseling sessions with both the surgical oncologist and a dedicated medical coordinator.
Top Hospitals for Melanoma Surgery
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Melanoma Surgery
Internationally trained specialists in Surgical Oncology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Dr. Belal Bin Asaf
MBBS, MS (Surgery), Fellowship in Thoracic Surgery, Certification as Robotic Console Surgeon, Observing Fellowship in VATS Lobectomy, Training in Minimally Invasive Esophagectomy
Thoracic Surgical Oncologist
Medanta — The Medicity, Gurugram, India
20+ Yearsof experience
Dr. Belal Bin Asaf is a distinguished Thoracic Surgical Oncologist and Director of Surgical Oncology at Medanta — The Medicity in Gurugram. With over 20 years of clinical experience, he has established himself as a pioneering leader in minimally invasive thoracic surgical oncology across India. His credentials include MBBS, MS in Surgery, Fellowship in Thoracic Surgery, and specialized certification as a Robotic Console Surgeon, combined with focused… Read more
Frequently Asked Questions — Melanoma Surgery
The total cost of melanoma surgery in India ranges from approximately USD 3,500 to USD 12,000, depending on the stage and complexity of the procedure. A straightforward wide local excision with sentinel lymph node biopsy for Stage I–II disease typically costs USD 3,500–6,000, while a therapeutic lymph node dissection, isolated limb perfusion, or cases requiring reconstructive flap surgery can reach USD 8,000–12,000. In the UAE (Dubai or Abu Dhabi), equivalent procedures are priced between USD 8,000 and USD 25,000 at JCI- and DHA-accredited centers such as Cleveland Clinic Abu Dhabi, American Hospital Dubai, and Mediclinic City Hospital. Both destinations include surgeon fees, anesthesia, operating room charges, histopathology, standard post-operative medications, and hospital stay in the package price. Adjuvant immunotherapy (pembrolizumab, nivolumab, or dabrafenib-trametinib) is priced separately per cycle and varies by drug and protocol duration. India offers a cost saving of 50–65% versus the UAE for the same oncological expertise and internationally accredited infrastructure. GAF Healthcare provides a fully itemized cost estimate tailored to your specific pathology and staging before you commit to travel.
The minimum in-country stay before safe international air travel depends directly on the type of procedure performed. For patients undergoing wide local excision with or without sentinel lymph node biopsy (Stage I–IIA), wound healing is typically sufficient by Days 14–21 post-surgery, allowing international flight after a 2–3 week stay. For patients who have undergone therapeutic lymph node dissection (axillary, inguinofemoral, or cervical), or those who required reconstructive flap surgery or skin grafting, a 4–6 week stay is recommended to ensure wound integrity, adequate drain management, and lymphedema stabilization before the physiological stresses of long-haul flight. Patients who commence adjuvant immunotherapy (e.g., pembrolizumab) in-country are reviewed after Cycle 1 (Day 21) before travel clearance is given, ensuring no severe immune-related adverse events are active. Fit-to-fly criteria assessed by your treating surgical oncologist include: complete wound closure without dehiscence, absence of active infection, drain removal, DVT risk stratification (compression stockings and anticoagulation prescribed for the flight), and hemodynamic stability. GAF Healthcare's case managers schedule your final pre-departure consultation and coordinate all discharge documentation, including a travel clearance letter, for airline or insurance purposes.
The success rate of melanoma surgery is strongly stage-dependent and is best understood through 5-year overall survival data from high-volume cancer centers. For Stage I melanoma (Breslow ≤2 mm, node-negative), surgical resection alone achieves a 5-year survival rate exceeding 90–98%, with local recurrence rates below 5% when margins are adequate. Stage II melanoma (thick tumors or ulcerated lesions, node-negative) has 5-year survival rates of 65–80% following wide local excision, and the addition of adjuvant pembrolizumab (per KEYNOTE-716) reduces the risk of recurrence by approximately 35% in high-risk Stage IIB–IIC patients. Stage III melanoma (regional lymph node involvement) treated with complete surgical resection plus 12 months of adjuvant anti-PD-1 immunotherapy (nivolumab per CheckMate 238, or pembrolizumab per KEYNOTE-054) achieves 5-year recurrence-free survival of 50–70% and overall survival of 60–75% at major centers. For BRAF V600-mutant Stage III patients, adjuvant dabrafenib plus trametinib reduces relapse risk by approximately 50%, with a 5-year overall survival benefit confirmed in long-term COMBI-AD data. Oligometastatic Stage IV disease treated with metastasectomy combined with systemic immunotherapy can achieve 5-year survival of 15–40% in selected patients. Key factors that independently predict better outcomes include: complete (R0) surgical resection with histologically clear margins, absence of ulceration in the primary tumor, low mitotic rate, BRAF mutation status (targetable with inhibitors), good performance status (ECOG 0–1), normal serum LDH, and access to adjuvant immunotherapy at a high-volume center. GAF Healthcare partner institutions in India and the UAE treat melanoma within multidisciplinary tumor boards that include surgical oncologists, dermatologists, medical oncologists, radiation oncologists, and plastic surgeons—a framework that consistently reproduces international benchmark survival outcomes.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully integrated non-medical support framework to ensure that international patients experience zero logistical friction from the moment of inquiry to post-treatment repatriation.
INDIA — VISA & ENTRY: GAF Healthcare facilitates the e-Medical Visa (eMV) application for India, which allows a stay of up to 60 days (extendable) and covers the patient plus one accompanying attendant on a Medical Attendant Visa. Required documents—hospital invitation letter, treatment cost estimate, valid passport, and passport-size photographs—are prepared by our team and submitted through the Indian government's online portal, with typical approval in 3–5 business days. Airport meets-and-greet with a dedicated GAF coordinator is arranged at all major Indian hubs (Delhi IGI, Mumbai CSIA, Chennai, Bengaluru, Hyderabad).
UAE — VISA & ENTRY: Citizens of over 50 countries (EU, UK, USA, Canada, GCC nationals) receive visa-free or visa-on-arrival access to the UAE for 30–90 days, making it the most frictionless destination for medical travel. For patients requiring a Medical Visit Visa, GAF Healthcare coordinates the application through the UAE partner hospital's international patient services desk (IPS), which is a DHA-approved facilitator. Entry to Dubai (DXB/DWC) and Abu Dhabi (AUH) is typically granted within 48–72 hours.
AIRPORT & GROUND TRANSFERS: All patients are received at the airport by a GAF-assigned medical escort or concierge representative. Wheelchair assistance, porter services, and air-conditioned private vehicle transfers to the hospital or accommodation are arranged in advance. Return airport transfers following discharge are likewise coordinated.
MEDICAL INTERPRETATION & TRANSLATION: GAF Healthcare provides certified medical interpreters in Arabic, Russian, French, Swahili, Bangla, Uzbek, and other languages. Interpreters accompany patients to all consultations, surgical consent sessions, and post-operative reviews. All hospital discharge summaries, pathology reports, operative notes, and imaging CDs are provided in English plus the patient's native language upon request.
ATTENDANT ACCOMMODATION & PATIENT SUPPORT: For patients accompanying an attendant (family member or nurse), GAF Healthcare pre-books serviced apartments or hotel rooms within 500 meters of the treating hospital, priced across a range of budgets. In-hospital attendant cot/recliner arrangements are coordinated with the ward team. Meal preferences, dietary restrictions, and prayer/religious requirements are communicated to the hospital's international patient services team in advance.
TELEMEDICINE & POST-DEPARTURE CONTINUITY: Upon discharge, each patient is assigned a GAF Healthcare case manager who remains accessible for 12 months. All medical records are digitized and shared via a secure patient portal. GAF coordinates remote follow-up consultations with the treating oncologist via video call, facilitates prescription renewal for adjuvant therapies, and liaises with the patient's home oncologist for seamless continuity of care.
Patients Also Explore
Other treatments commonly sought by patients considering Melanoma Surgery.
Breast Cancer Treatment
Cancer Care
Lung Cancer Treatment
Cancer Care
Colonoscopy & Polypectomy
Gastroenterology
Hepatitis B Treatment
Gastroenterology